258 related articles for article (PubMed ID: 18029023)
1. The A3 adenosine receptor: an enigmatic player in cell biology.
Gessi S; Merighi S; Varani K; Leung E; Mac Lennan S; Borea PA
Pharmacol Ther; 2008 Jan; 117(1):123-40. PubMed ID: 18029023
[TBL] [Abstract][Full Text] [Related]
2. Selective upregulation of the A3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma.
Schlötzer-Schrehardt U; Zenkel M; Decking U; Haubs D; Kruse FE; Jünemann A; Coca-Prados M; Naumann GO
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2023-34. PubMed ID: 15914619
[TBL] [Abstract][Full Text] [Related]
3. Animal models for the study of adenosine receptor function.
Yaar R; Jones MR; Chen JF; Ravid K
J Cell Physiol; 2005 Jan; 202(1):9-20. PubMed ID: 15389588
[TBL] [Abstract][Full Text] [Related]
4. A3 adenosine receptor: pharmacology and role in disease.
Borea PA; Gessi S; Bar-Yehuda S; Fishman P
Handb Exp Pharmacol; 2009; (193):297-327. PubMed ID: 19639286
[TBL] [Abstract][Full Text] [Related]
5. Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype.
Gessi S; Merighi S; Varani K; Cattabriga E; Benini A; Mirandola P; Leung E; Mac Lennan S; Feo C; Baraldi S; Borea PA
J Cell Physiol; 2007 Jun; 211(3):826-36. PubMed ID: 17348028
[TBL] [Abstract][Full Text] [Related]
6. [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor.
Klotz KN; Falgner N; Kachler S; Lambertucci C; Vittori S; Volpini R; Cristalli G
Eur J Pharmacol; 2007 Feb; 556(1-3):14-8. PubMed ID: 17126322
[TBL] [Abstract][Full Text] [Related]
7. Identification of adenosine A1 and A3 receptor subtypes in rat pial and intracerebral arteries.
Di Tullio MA; Tayebati SK; Amenta F
Neurosci Lett; 2004 Aug; 366(1):48-52. PubMed ID: 15265588
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor.
Ohana G; Bar-Yehuda S; Barer F; Fishman P
J Cell Physiol; 2001 Jan; 186(1):19-23. PubMed ID: 11147810
[TBL] [Abstract][Full Text] [Related]
9. The A3 adenosine receptor: history and perspectives.
Borea PA; Varani K; Vincenzi F; Baraldi PG; Tabrizi MA; Merighi S; Gessi S
Pharmacol Rev; 2015; 67(1):74-102. PubMed ID: 25387804
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of adenosine A3 receptors controls adenosine A2A receptor-mediated inhibition of TLR responses in microglia.
van der Putten C; Zuiderwijk-Sick EA; van Straalen L; de Geus ED; Boven LA; Kondova I; IJzerman AP; Bajramovic JJ
J Immunol; 2009 Jun; 182(12):7603-12. PubMed ID: 19494284
[TBL] [Abstract][Full Text] [Related]
11. N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor.
Volpini R; Dal Ben D; Lambertucci C; Taffi S; Vittori S; Klotz KN; Cristalli G
J Med Chem; 2007 Mar; 50(6):1222-30. PubMed ID: 17309246
[TBL] [Abstract][Full Text] [Related]
12. A3 adenosine receptor-mediated protection of the ischemic heart.
Headrick JP; Peart J
Vascul Pharmacol; 2005; 42(5-6):271-9. PubMed ID: 15922260
[TBL] [Abstract][Full Text] [Related]
13. 2,9-disubstituted-N6-(arylcarbamoyl)-8-azaadenines as new selective A3 adenosine receptor antagonists: synthesis, biochemical and molecular modelling studies.
Biagi G; Bianucci AM; Coi A; Costa B; Fabbrini L; Giorgi I; Livi O; Micco I; Pacchini F; Santini E; Leonardi M; Nofal FA; Salerni OL; Scartoni V
Bioorg Med Chem; 2005 Aug; 13(15):4679-93. PubMed ID: 15908217
[TBL] [Abstract][Full Text] [Related]
14. Purinergic receptors in gastrointestinal inflammation.
Kolachala VL; Bajaj R; Chalasani M; Sitaraman SV
Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G401-10. PubMed ID: 18063703
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma.
Okamura T; Kurogi Y; Hashimoto K; Sato S; Nishikawa H; Kiryu K; Nagao Y
Bioorg Med Chem Lett; 2004 Jul; 14(14):3775-9. PubMed ID: 15203160
[TBL] [Abstract][Full Text] [Related]
16. 5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.
Da Settimo F; Primofiore G; Taliani S; Marini AM; La Motta C; Simorini F; Salerno S; Sergianni V; Tuccinardi T; Martinelli A; Cosimelli B; Greco G; Novellino E; Ciampi O; Trincavelli ML; Martini C
J Med Chem; 2007 Nov; 50(23):5676-84. PubMed ID: 17927167
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands.
Federico S; Spalluto G
Expert Opin Ther Pat; 2012 Apr; 22(4):369-90. PubMed ID: 22435652
[TBL] [Abstract][Full Text] [Related]
18. Activation of the adenosine-A3 receptor stimulates matrix metalloproteinase-9 secretion by macrophages.
Velot E; Haas B; Léonard F; Ernens I; Rolland-Turner M; Schwartz C; Longrois D; Devaux Y; Wagner DR
Cardiovasc Res; 2008 Nov; 80(2):246-54. PubMed ID: 18653544
[TBL] [Abstract][Full Text] [Related]
19. IB-MECA and cardioprotection.
Xu Z; Jang Y; Mueller RA; Norfleet EA
Cardiovasc Drug Rev; 2006; 24(3-4):227-38. PubMed ID: 17214599
[TBL] [Abstract][Full Text] [Related]
20. QSAR study on thiazole and thiadiazole analogues as antagonists for the adenosine A1 and A3 receptors.
Borghini A; Pietra D; Domenichelli P; Bianucci AM
Bioorg Med Chem; 2005 Sep; 13(18):5330-7. PubMed ID: 15990318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
